Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleSupplement

CXCR4 Ligands: The Next Big Hit?

Annemiek M.E. Walenkamp, Constantin Lapa, Ken Herrmann and Hans-Jürgen Wester
Journal of Nuclear Medicine September 2017, 58 (Supplement 2) 77S-82S; DOI: https://doi.org/10.2967/jnumed.116.186874
Annemiek M.E. Walenkamp
1Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Constantin Lapa
2Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Herrmann
3Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
4Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Jürgen Wester
5Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany; and
6Scintomics GmbH, Fuerstenfeldbruck, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Some key signaling pathways thought to be involved in CXCR4–CXCL12 signaling. On agonistic binding to CXCR4, CXCL12 is internalized and finally subjected to lysosomal degradation. Activation of CXCR4 induces β-arrestin–mediated signaling. On the basis of their sequence similarity, Gα subunits are divided into 4 families (Gαs, Gαi, Gαq, and Gα12) that regulate G protein–coupled receptor signals via different routes.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Maximum-intensity projections of different tumor entities undergoing 68Ga-pentixafor PET/CT: multiple myeloma, diffuse large B-cell lymphoma (DLBCL), T-cell prolymphocytic leukemia (T-PLL), adrenocortical carcinoma (ACC), and small cell lung cancer (SCLC).

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (Supplement 2)
Journal of Nuclear Medicine
Vol. 58, Issue Supplement 2
September 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
CXCR4 Ligands: The Next Big Hit?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
CXCR4 Ligands: The Next Big Hit?
Annemiek M.E. Walenkamp, Constantin Lapa, Ken Herrmann, Hans-Jürgen Wester
Journal of Nuclear Medicine Sep 2017, 58 (Supplement 2) 77S-82S; DOI: 10.2967/jnumed.116.186874

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
CXCR4 Ligands: The Next Big Hit?
Annemiek M.E. Walenkamp, Constantin Lapa, Ken Herrmann, Hans-Jürgen Wester
Journal of Nuclear Medicine Sep 2017, 58 (Supplement 2) 77S-82S; DOI: 10.2967/jnumed.116.186874
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • TARGETING OF CXCR4–CXCL12 AXIS
    • ROLE OF CXCR4–CXCL12 IN TUMOR CELL–MICROENVIRONMENT INTERACTIONS
    • ROLE OF CXCR4–CXCL12 IN IMMUNITY IN TUMOR MICROENVIRONMENT
    • CXCR4 RECEPTOR IMAGING AND CXCR4-DIRECTED RADIONUCLIDE THERAPY
    • CONCLUSION
    • DISCLOSURE
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • ERK signaling drives evolutionary expansion of the mammalian cerebral cortex
  • CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma
  • Biokinetics and Dosimetry of 177Lu-Pentixather
  • Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
  • VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1
  • PET Radiopharmaceuticals: Whats New, Whats Reimbursed, and Whats Next?
  • Theranostic Concepts: More Than Just a Fashion Trend--Introduction and Overview
  • Google Scholar

More in this TOC Section

  • Is the Amyloid Imaging Tsunami Really Happening?
  • Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition
  • A New Dawn
Show more Supplement

Similar Articles

Keywords

  • CXCR4
  • tumor microenvironment
  • immunotherapy
  • endoradiotherapy
SNMMI

© 2025 SNMMI

Powered by HighWire